The Munich-based biotech company 2NA FISH GmbH, developer of an innovative platform for spatial RNA biomarker detection in oncology diagnostics, has secured additional pre-seed funding. The round was led by GF BRYCK Ventures, with a follow-on investment from existing investor Twip.
The capital will be used to further develop and validate 2NA FISH’s spatial RNA biomarker detection platform for research and translational use, expand early-access collaborations, and strengthen the software stack that enables robust analysis in routine pathology workflows.
2NA FISH’s platform combines nanostructure-enhanced probes with routine pathology workflows to deliver bright, specific signals and practical multiplexing on standard fluorescence microscopes - aiming to make spatial RNA biomarker testing more affordable and deployable in everyday lab and pathology settings. A proprietary, AI-based analysis application supports quantification and cell-level readouts to turn spatial RNA data into actionable biomarker information.
“This additional funding helps us translate strong lab results into real-world relevance - completing key validation milestones, broadening early-access collaborations, and hardening the software stack that research and pathology teams need,” says Christina Port, Founder and CEO of 2NA FISH.
The investors are convinced by the progress and potential of the technology: 2NA FISH combines scientific depth with a clear path to application, which could drive broad adoption in both research and diagnostics. Twip also reaffirms its confidence in the team and is impressed by the rare combination of innovation, execution strength, and vision.
To the original press release.